BPC-157 vs TB-500 Comparison Table The table below summarises how the two peptides are characterised across the preclinical literature
*Please note: The half-life of T4/T3 combination medications may vary per formulation (this can vary depending on the formulation and whether it is an immediate or sustained release version), so some people may have a falsely suppressed TSH, even at the euthyroid state (or the state of normal thyroid function), when taking T3-containing medications
Semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda) often run about $950 to $1,400 per month
BENEFITS Dual receptor activation studied for simultaneous GIP and GLP-1 receptor engagement Metabolic research explored for body weight and composition changes in clinical trials Glycemic control linked to improvements in glucose homeostasis models Comparative studies frequently assessed alongside semaglutide in head-to-head research Incretin biology investigated for advancing understanding of dual-agonist pharmacology WHAT RESEARCHERS LOOK AT Dual GIP/GLP-1 receptor binding and activation profiles Comparative efficacy vs mono-agonists (semaglutide, liraglutide) Dose-dependent metabolic and body composition effects Insulin sensitivity and beta-cell function modeling Pharmacokinetic profiling and half-life analysis
They are most likely to work best if started immediately after an injection
TB-500 may be more useful for systemic inflammation control, circulation, and global recovery
